Abstract Aggrecan and cartilage oligomeric matrix protein (COMP) which are important degradation products of articular cartilage may be promising diagnostic markers in serum and/or synovial fluid for diagnosis of knee osteoarthritis (OA). Our objective was to measure serum and synovial fluid levels of aggrecan and COMP in patients with OA of the knee joint to find out if they could be of diagnostic value in OA and if their levels correlate with the clinical and radiological manifestations of the disease. Sixty-six patients suffering from primary knee OA with effusion (26 males and 40 females) were studied. Twenty individuals (six males and 14 females) with recent traumatic knee effusion matched for age and sex were chosen to serve as a control group. All subjects had thorough clinical and radiological (X-ray and MRI) evaluation. Aggrecan and COMP in serum and synovial fluid were measured by ELISA. Serum and synovial fluid aggrecan and COMP levels were significantly higher than the control. Serum and synovial fluid aggrecan and COMP levels were positively correlated with age, body mass index, disease duration, plain X-ray and MRI scores. In OA, serum and synovial fluid aggrecan and COMP levels are elevated and represent useful markers in the diagnosis. Moreover, these elevated levels positively correlated with radiological joint damage but not with clinical disease parameters. These markers have the potential to be used for monitoring articular cartilage destruction and response to different therapeutic modalities.
Introduction
Osteoarthritis (OA) is a disease of complex etiology that occurs as a result of both mechanical and biological events. The most established method for assessing joint damage in OA is joint space width (JSW) measurement using plain Xrays [1, 2] . However, when radiological diagnosis is established, significant joint damage has often already occurred, as the arthrosis is initiated long before the radiographic diagnosis can be effected, and the diagnosis will only be made late in the disease [3] . Clearly, to identify patients with a high risk for destructive OA and to monitor drug efficacy, more sensitive techniques than plain X-ray are needed [4] . Magnetic resonance imaging (MRI) is currently being optimised for this purpose [5] . Alternatively, specific and sensitive biochemical markers (aggrecan and COMP) reflecting abnormalities of the turnover of bone, cartilage, and synovial tissues are increasingly used as helpful tools in early diagnosis before irreversible damage has occurred [6] .
The aim of the present study was to measure serum and synovial fluid levels of aggrecan and cartilage oligomeric matrix protein (COMP) in patients with OA of the knee joint to evaluate their potential utility as diagnostic biomarkers for knee OA and to correlate their levels with the clinical and radiological manifestations of the disease. Specifically, we aimed to compare the levels of aggrecan and COMP in the serum and synovial fluid of patients with osteoarthritic and post-traumatic knee effusions. In addition, we aimed to correlate the levels of aggrecan and COMP with patient age and BMI. Finally, we wished to assess if the level of aggrecan and COMP could be correlated to disease severity as assessed by radiographic and MRI assessment of disease severity.
Materials and methods
This prospective, controlled study was conducted on 66 consecutive patients with primary OA of the knee joint with effusion, who were attending the outpatient clinic of Rheumatology and Rehabilitation, Mansoura University Hospital, Egypt. The visits were prompted by the acute onset of pain and swelling and stiffness in the affected knees. There were 26 males and 40 females, and their ages ranged from 45 to 60 years. Disease duration ranged from 2 to 8 years. Patients were diagnosed according to the American College of Rheumatology criteria for diagnosis of primary knee OA [7] . Twenty individuals (six males and 14 females) with recent traumatic knee effusion were chosen from the Casualty Department, Mansoura University Hospital, to serve as a control group. All of these patients had suffered knee injury within 1 week of presentation but had no evidence of fracture or meniscal injury. They were matched for age and sex with the OA group. Their ages ranged from 40 to 55 years. Written consent was obtained from every subject in this study after IRB approval was obtained.
Patients were excluded if they presented with secondary OA, previous knee injury or intra-articular fracture, steroid injection into the affected knee joint within 3 months of recruitment for the study, OA in joints other than the knee joint, osteoporosis and other rheumatic diseases. Also, we excluded patients with inflammed joints other than knee joint as this could affect serum levels of the biomarkers.
Each subject recruited into this study was evaluated with a thorough history and physical examination (Table 1) . Height and weight were measured on the day of the visit to calculate the BMI. Pain severity was assessed using visual analogue scale ranging from a score of 1 representing mild pain to 10 representing extreme pain. The Vas line was 10 cm in length [8] . Tenderness was assessed on a rating scale of 0-3 [9] . The Quadriceps muscle was evaluated by thigh circumference measurement and quadriceps wasting was graded [10] . Joint effusion was graded on a scale of 0-3 [10] . Both active and passive ranges of motion (ROM) were tested, noting any pain elicited and loss of motion. Measurement was carried out using the standard full circle plastic goniometer. Maximum flexion and extension lag were graded [11] . Disease severity was assessed according to Lequesne et al. [12] with scoring range from 0-24. Functional assessment was done using the Western Ontario and McMaster (WOMAC) OA index that measure pain, joint stiffness and degree of difficulty to carry out daily life activity with scoring range from 0 to 96 [13] . Plain X-ray was done for the knees in anteroposterior (weight-bearing) and lateral views, and radiographs were scored from 0 to 4 depending upon X-ray findings [14] . MRI was performed for all cases [15] and the MRI was evaluated by a single observer blinded to the biomarker levels. MRI findings of interest included decrease of cartilage thickness, the presence of osteophytes, subchondoral cysts and subchondoral sclerosis.
Venous blood sample was withdrawn from each subject by sterile venipuncture during this office evaluation. The separated serum was kept frozen at −20 C till the time of estimation of aggrecan and COMP.
Aspiration of the knee joint fluid was done for the patients under complete aseptic conditions also during this office evaluation. About 10 mL of synovial fluid was collected from each knee collected into specimen tubes and centrifuged for 20 min. The supernatant fluid was stored at −20°C until analyzed. The knee joint was then aspirated to completion [16] . Quantitative measurement of aggrecan level was performed on the serum and synovial fluid samples using an immunoenzymetric technique [17] . The kit was manufactured by Medgenix Diagnostics S.A., Zoning Industrial, B-6220 Fleurus, Belgium. In this method, monoclonal antibodies (MAbs) directed against distinct epitopes of aggrecan are used. Standards or samples containing aggrecan (AG) react with capture monoclonal antibody (MAb 1) coated on the microtiter well and with a monoclonal antibody (MAb 2) labelled with horseradish peroxidase (HRP). After an incubation period allowing the formation of a sandwich: coated MAb 1-AG-MAb 2-HRP, the microtiter plate is washed to remove unbound enzyme-labelled antibodies. Bound enzyme-labelled antibodies are measured through a chromogenic reaction. Chromogenic solution is added and incubated. The reaction is stopped with the addition of stop solution and the microtiter plate is then read at 450 nm. The colour is proportional to the AG concentration.
Quantitative measurement of COMP level: The kit was supplied by Wieslab, IDEON Research Park Lund, S-223, Sweden. COMP Assay Kit is an enzyme immunoassay for the quantitation of intact or fragmented human cartilage oligomeric matrix protein in serum or synovial fluid. The assay utilizes native human articular COMP coated to well microtiter plates and a rabbit polyclonal antiserum directed to human COMP. Bound antibody is detected using an alkaline phosphatase-labelled anti-rabbit IgG conjugate.
Statistical analysis of the results was carried out using the SPSS (statistical package for social science) Version 10. To test the data distribution, the Kolmogrove Smirnove test was used which revealed the data to be parametric. Data are expressed as mean ± standard deviation (X±SD ). Statistical analysis between the OA patient group and recent post traumatic control group was done using the student's t test. Correlation study of the OA group was using Pearson's correlation coefficient (r).
Results
Patients with OA were found to have higher aggrecan and COMP levels in both serum (p=0.001) and synovial fluid (p=0.004) compared with controls (Tables 2 and 3 ).
The body mass index in OA patients (34.5±1.99 kg/m 2 ) was significantly higher than controls (27.3±1.98 kg/m 2 ; p<0.001).
Both serum and synovial fluid aggrecan and COMP levels in the patients with OA were positively correlated with age, body mass index, disease duration, plain X-ray and MRI scores. Meanwhile, no significant correlations were observed between serum and synovial fluid aggrecan or COMP and morning stiffness, pain, periarticular tenderness, quadriceps wasting, effusion volume, maximum flexion, the presence of an extension lag or the disease severity as assessed by the method of Lequesne et al. [12] ( Tables 4 and 5 ).
Discussion
Much attention has been focused on biomarkers such as cartilage-derived macromolecules or their fragments whose release into the circulation from the joint may reflect disturbances in joint tissue turnover [18, 19] . In addition, cartilage-specific markers, such as aggrecan and COMP have been detected in serum and synovial fluid, and their relevance in the pathogenesis of osteoarthritis needs to be determined [20] . This study aimed to measure serum and synovial fluid levels of aggrecan and COMP in patients with OA of the knee joint to find out if they could be of diagnostic value in OA. Specifically, we aimed to compare the levels of aggrecan and COMP in the serum and snovial fluid of patients with osteoarthritic and post-traumatic knee effusions. In addition, we aimed to correlate the levels of aggrecan and COMP with patient age and BMI. Finally, we wished to assess if levels of aggrecan and COMP could be correlated to disease severity as assessed by radiographic and MRI assessment of disease severity. We selected patients with recent traumatic effusions as controls since it is difficult and perhaps unethical to obtain synovial fluid from completely healthy volunteers. In this study, both serum and synovial fluid aggrecan and COMP levels were significantly higher in patients with knee OA than controls. Elevated levels of aggrecan epitopes and COMP in OA patients probably reflect an increased synthesis of aggrecan in degenerated cartilage or increased degradation with a resultant loss from the cartilage [18, [21] [22] [23] [24] [25] [26] [27] [28] . However, Fuller et al. [29] studied the level of aggrecan epitopes in OA synovial fluid and compared the results with that of the contralateral joint. They found no significant difference between the two sides, which could be explained by the fact that the contralateral joint is not necessarily normal to be used as a control.
In this study, the synovial fluid aggrecan or COMP was several times higher than serum levels. This result suggests that aggrecan and COMP are locally produced in the joint and high synovial fluid of these biomarkers are associated with rapid cartilage turnover [14, 23, 30] .
In this study, serum and synovial fluid aggrecan levels and COMP were positively correlated with age and body mass index. In fact, it is well recognized that obesity and aging are important factors in OA knees [22, 26, 31, 32] . However, these results disagree with some authors [30, [33] [34] [35] ,
In this study, serum and synovial fluid aggrecan and COMP were positively correlated with disease duration. This may be explained by the fact that long duration of the disease is likely to result in more cartilage destruction with consequent release of aggrecan into the joint fluid which then appears in the serum. These findings are in agreement with that reported in some literatures [30, 36, 37] . However, Sharif et al. [38] and Conrozier et al. [35] disagreed with our findings and postulated that increased expression of these epitopes might reflect the response of the articular cartilage to insult requiring initiation of a high level. No significant correlations could be detected between aggrecan or COMP levels and any of the clinical symptoms and signs (morning stiffness, pain, local knee warmth, periarticular tenderness, quadriceps wasting, joint effusion, synovial thickening, maximum flexion as well as extension lag). Furthermore, no significant correlation could be detected between aggrecan or COMP levels and Lequesne functional index, as well as WOMAC score. These findings could be explained by the fact that clinical evaluation does not necessarily reflect cartilage changes as no close link between such parameters and the tissue process was to be expected [32, 35, 39, 40] . These results disagree with those of Campion et al. [41] , Thonar et al. [42] and Bleasel et al. [30] who reported that aggrecan turnover correlated positively with the clinical signs of knee OA. Moreover, Sharif et al. [38] found that COMP levels significantly correlated with activity and severity of knee OA.
Significant correlations were observed between serum and synovial fluid aggrecan or COMP levels and plain Xray score or MRI score since advanced disease, as expressed by higher radiological score, was associated with more cartilage destruction with subsequent increased release of aggrecan into joint fluid and serum. These results are in agreement with some authors [29, [43] [44] [45] [46] [47] . On the other hand, Belcher et al. [33] and Fragonas et al. [48] could not detect any significant correlation between the markers in synovial fluid and radiological findings. This is probably related to differences in patient selection.
It could be concluded that serum and synovial fluid aggrecan and COMP levels are elevated and represent useful markers in the diagnosis of knee OA. Moreover, these elevated levels positively correlated with radiological joint damage but not with clinical disease parameters. Promisingly, these markers have the potential to be used for monitoring articular cartilage destruction and response to different therapeutic modalities.
